We are live on ! Find out more
ABEO icon

Abeona Therapeutics

70 hedge funds and large institutions have $43.4M invested in Abeona Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 24 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more call options, than puts

Call options by funds: $209K | Put options by funds: $204K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.15% less ownership

Funds ownership: 1.26%1.11% (-0.15%)

7% less funds holding

Funds holding: 7570 (-5)

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

25% less capital invested

Capital invested by funds: $58.2M → $43.4M (-$14.8M)

50% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 24

Holders
70
Holders Change
-5
Holders Change %
-6.67%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
12
Reduced
24
Closed
23
Calls
$209K
Puts
$204K
Net Calls
+$5K
Net Calls Change
-$180K

ABEO Hedge Fund Activity: Q2 2021 in Review

70 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2021, worth a combined $43.4M — down 25% from $58.2M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of ABEO and 18 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 12 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $2.24M. The largest seller was BlackRock, cutting an estimated $5.44M.

  • 70 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2021, down from 75 in Q1 2021.
  • Funds reported $43.4M of Abeona Therapeutics stock for Q2 2021, down 25% quarter-over-quarter.
  • 18 funds opened new Abeona Therapeutics positions in Q2 2021 and 23 closed out, a net change of -5 holders.
  • The largest Abeona Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $2.24M added.
  • The largest Abeona Therapeutics seller in Q2 2021 was BlackRock, an estimated $5.44M sold.

Based on aggregated 13F filings for Q2 2021.